Recce Pharmaceuticals Limited has received ethics approval from Indonesia’s Human Research Ethics Committee to initiate Phase 3 clinical trials of its topical gel, RECCE® 327 (R327G), designed for diabetic foot infections (DFIs). This green light enables the Australian-based company to move forward with its large-scale study in Indonesia, a country with one of the world’s […]
Recce Pharmaceuticals Limited recently announced significant progress in its phase II clinical trial for RECCE 327 Topical Gel (R327G), an innovative treatment for acute bacterial skin and skin structure infections (ABSSSI). An independent non-Data Safety Monitoring Board (non-DSMB) reviewed the interim safety and efficacy data, affirming R327G’s safety and tolerability. In addition, highly encouraging efficacy […]
Recce Pharmaceuticals Ltd (ASX:RCE, FSE:R9Q) continues its trajectory in pioneering a new class of Synthetic Antiinfectives, spotlighting its recent achievement. The company announced that Scientia Clinical Research has successfully finalized cohort dosing for both male and female subjects. This is part of the crucial Phase I/II UTI/Urosepsis clinical trial, focusing on evaluating the performance of […]